Step aside, CAR-Ts; with three FDA approvals, the class of bispecific antibodies has begun to take on the relapsed/refractory multiple myeloma treatment segment. Currently, the FDA has authorized 10 bispecific antibodies and one bispecific molecule, the majority of which are approved for oncology indications, mostly hematological malignancies (mainly multiple myeloma and diffuse large B-cell lymphoma … Continue reading A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray